Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Atopic Dermatitis Ad Epidemiology Forecast

DelveInsight’s ‘Atopic Dermatitis (AD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Atopic Dermatitis (AD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, Spain, Italy, France, and United Kingdom)
  • Japan

Study Period: 2018–2030

Atopic Dermatitis (AD) Understanding

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.

 

AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.

 

There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. Occasionally, patients carrying an AD diagnosis may display atypical clinical features, chronic dermatoses, infectious processes, and primary immunodeficiency may mimic the presentation leading to the differential diagnosis. Noninfectious dermatoses include contact dermatitis, seborrheic dermatitis, and psoriasis.

 

At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

Atopic Dermatitis (AD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population, Gender-specific Distribution of Atopic Dermatitis in Adults, and Chronic Pruritus Prevalence in Atopic Dermatitis in the adults in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan market from 2018 to 2030.

 

Key Findings

This section provides glimpse of the AD epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  • The total diagnosed prevalent population of AD in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan was estimated to be 25,091,967 in 2020.
  • Epidemiology assessed for AD showed that the US, in 2020, accounted for approximately 32,197,083 prevalent cases of AD.
  • In the EU5 countries, the prevalent population of AD was maximum in UK with 7,195,160 cases, followed by the France with 6,585,281 cases in 2020. While, the least number of cases were in Spain, with 4,678,148 cases in 2020.
  • Japan accounted for 9,510,049 prevalent AD cases in 2020.
  • The number of chronic pruritus adult prevalent population of AD in the United States is estimated to be 13,643,033 in 2020.
  • The total diagnosed prevalent population of AD in the seven major markets was found to be 52,941,993 in 2020. In the case of AD patients in the United States, the diagnosed prevalent cases were estimated to be 24,039,022 in 2020.
  • As per the analysis, a higher percentage of mild AD was observed in the 7MM, followed by moderate AD and severe AD in 2020 in the case of both children and adults. In the US, mild AD accounted for the highest cases in 2020, followed by moderate AD with 9,631,982 and 4,638,631, respectively. In contrast, the lowest cases were found in severe AD, with 1,765,569 cases, in 2020.
  • Among the gender-specific prevalent contribution, females are affected more by AD than males. In 2020, there were 6,039,851 prevalent cases of AD in males and 10,010,776 prevalent cases in females in the US.

Country-Wise Atopic Dermatitis (AD) Epidemiology

The epidemiology segment also provides the Atopic Dermatitis (AD) epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Scope of the Report

  • The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the historical and forecasted patient pool covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Atopic Dermatitis (AD).
  • The report provides the segmentation of the disease epidemiology for the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis in Adults, etc.

Report Highlights

  • Ten Year Forecast of Atopic Dermatitis (AD)
  • The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Coverage
  • Total prevalent population of Atopic Dermatitis (AD).
  • Total diagnosed prevalent population of Atopic Dermatitis (AD).
  • Delvelnsight has analysed gender-specific distribution of AD. As per the analysis, AD is more prevalent in females than in males.
  • In addition, severity-specific data of AD was analyzed, according to which the adult and pediatric population of AD can be categorized as mild, moderate and severe AD. As per the DelveInsight estimates, it has been found that the mild form of AD included maximum cases, while minimum number of cases were found in severe form of AD in both the populations. This trend is clearly evident in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan for the study period 2018–2030.

Analyst Comments

Various epidemiology studies and international surveys on the prevalence of AD have been conducted in the the 7MM. Data from these studies indicate that AD is a common skin disease in both children and adults, predominantly in the adult female population. Some studies have also indicated a three-fold increase in the past few decades.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Atopic Dermatitis (AD)?
  • What is the historical Atopic Dermatitis (AD) patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan?
  • What would be the forecasted patient pool of Atopic Dermatitis (AD) at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan level?
  • What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan with respect to the patient population pertaining to Atopic Dermatitis (AD)?
  • At what CAGR the population is expected to grow in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan during the forecast period (2021–2030)?

Reasons to buy

The Atopic Dermatitis (AD) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Atopic Dermatitis (AD) market.
  • Quantify patient share distribution in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan for Atopic Dermatitis (AD).
  • The Atopic Dermatitis (AD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Atopic Dermatitis (AD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Atopic Dermatitis Market Overview at a Glance

5.1. Market Share (%) Distribution by Class of Therapies of Atopic Dermatitis in 2020

5.2. Market Share (%) Distribution by Class ofTherapies of Atopic Dermatitis in 2030

6. Disease Background and Overview

6.1. Signs and Symptoms

6.2. Causes and Triggers

6.3. Clinical presentation

6.4. Pathophysiology

6.5. Skin hypersensitivity – abnormalities of the horny cell layer

6.5.1. Mechanisms involved in inflammation

6.5.2. Pruritus

6.6. Biomarkers

6.6.1. Serum IgE levels

6.6.2. Peripheral eosinophil count

6.6.3. Serum lactate dehydrogenase level

6.6.4. Serum thymus and activation regulated chemokine level

6.7. Characteristics of eruption

6.7.1. Infancy (younger than 2 years)

6.7.2. Childhood/school-age (2–12 years old)

6.7.3. Adolescence/adulthood (13 years and older)

6.8. Differential diagnosis

6.9. Prevention and Management

6.10. Diagnosis

6.11. Diagnostic criteria for eczema

7. AD Clinical Guideline: American Academy of Dermatology Association (2014)

7.1. Guidelines for Diagnosis and Assessment

7.1.1. Recommendation for the diagnosis of AD

7.1.2. Recommendations for the use of biomarkers in the assessment of AD

7.1.3. Recommendations for disease severity and clinical outcomes assessment

7.1.4. Recommendations for the assessment of clinical associations of atopic dermatitis

8. Atopic eczema in under 12s: Diagnosis and management by NICE (updated 2020)

8.1. Assessment of severity, psychological and psychosocial well being, and quality of life

8.1.1. Identification and management of trigger factors

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology Methodology

9.3. 7MM Prevalent Population of Atopic dermatitis

9.4. 7MM Diagnosed Prevalent Population of Atopic dermatitis

9.5. Assumption and Rationale

9.5.1. United States

9.5.2. EU5

9.5.3. Japan

9.6. The United States

9.6.1. Diagnosed Prevalent Population of Atopic Dermatitis in the United States

9.6.2. Severity-specific distribution of Atopic Dermatitis in Adults in the United States

9.6.3. Severity-specific distribution of AD in Pediatric Population in the United States

9.6.4. Gender-specific Prevalence of Atopic Dermatitis in adults in the United States

9.6.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in the United States

9.7. EU5

9.7.1. Diagnosed Prevalent Population of Atopic Dermatitis in EU5

9.7.2. Severity-specific distribution of Atopic Dermatitis in Adults in EU5

9.7.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in EU5

9.7.4. Gender-specific Cases of Atopic Dermatitis (AD) in EU5

9.7.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in EU5

9.8. Japan

9.8.1. Diagnosed Prevalent Population of Atopic Dermatitis in Japan

9.8.2. Severity-specific distribution of Atopic Dermatitis in Adults in Japan

9.8.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in Japan

9.8.4. Gender-specific Prevalence of Atopic Dermatitis in adults in Japan

9.8.5. Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan

10. Organizations contributing towards AD

11. Patient Journey

12. Appendix

12.1. Bibliography

12.2. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Table

Table 1: Summary of Atopic Dermatitis Market and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Characteristic features of Atopic Dermatitis by age

Table 4: Diagnostic features for eczema

Table 5: Hanifin and Rajka Criteria for Atopic Dermatitis

Table 6: UK working party diagnostic criteria for eczema

Table 7: Topical Corticosteroids Ranked by Potency (from Most Potent to Least Potent)

Table 8: Features to be considered in the diagnosis of patients with AD

Table 9: Total Prevalent Population of Atopic dermatitis in the US (2018–2030)

Table 10: Diagnosed Prevalent Population of Atopic dermatitis in the US (2018–2030)

Table 11: Diagnosed Prevalent Population of AD in US (2018–2030)

Table 12: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2018–2030)

Table 13: Severity-specific distribution of AD in Pediatric Population in the US (2018–2030)

Table 14: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2018–2030)

Table 15: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2018–2030)

Table 16: Total Prevalent Population of AD in EU5 (2018–2030)

Table 17: Total Diagnosed Prevalent Population of AD in EU5 (2018–2030)

Table 18: Severity-specific Cases of AD in EU5 (2018–2030)

Table 19: Severity-specific Cases of AD in Pediatric Population EU5 (2018–2030)

Table 20: Gender-specific Cases of AD in EU5 (2018–2030)

Table 21: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2018–2030)

Table 22: Prevalent Population of Atopic Dermatitis in Japan (2018–2030)

Table 23: Diagnosed Prevalent Population of AD in Japan (2018–2030)

Table 24: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2018–2030)

Table 25: Severity-specific distribution of AD in Pediatric Population in Japan (2018–2030)

Table 26: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2018–2030)

Table 27: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2018–2030)

Table 28: Organizations contributing toward AD

List of Figures

Figure 1: Algorithm for the management of AD

Figure 2: Medical algorithm for the therapeutic management of AD in early childhood, based on the severity

Figure 3: Total Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)

Figure 4: Diagnosed Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)

Figure 5: Diagnosed Prevalent Population of Atopic Dermatitis in the US (2018–2030)

Figure 6: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2018–2030)

Figure 7: Severity-specific distribution of AD in Pediatric Population in the US (2018–2030)

Figure 8: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2018–2030)

Figure 9: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2018–2030)

Figure 10: Total Prevalent Population of AD in EU5 (2018–2030)

Figure 11: Total Diagnosed Prevalent Population of AD in EU5 (2018–2030)

Figure 12: Severity-specific Cases of AD in Adults in EU5 (2018–2030)

Figure 13: Severity-specific Cases of AD in Pediatric Population in EU5 (2018–2030)

Figure 14: Gender-specific Cases of AD in EU5 (2018–2030)

Figure 15: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2018–2030)

Figure 16: Prevalent Population of Atopic Dermatitis in Japan (2018–2030)

Figure 17: Diagnosed Prevalent Population of Atopic Dermatitis in Japan (2018–2030)

Figure 18: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2018–2030)

Figure 19: Severity-specific distribution of AD in Pediatric Population in Japan (2018–2030)

Figure 20: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2018–2030)

Figure 21: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2018–2030)

Forward to Friend

Need A Quote